☆ 4.7 Article

Tegaserod maleate exhibits antileukemic activity by targeting TRPM8

BIOMEDICINE & PHARMACOTHERAPY (2022)

Related references

Note: Only part of the references are listed.

Letter Gastroenterology & Hepatology

Global prediction of primary liver cancer incidences and mortality in 2040

Chenxi Li et al.

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Tegaserod: What's Old Is New Again

Gregory S. Sayuk et al.

Summary: Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) have a significant impact on the quality of life of affected individuals. Tegaserod, a 5-HT4 agonist, was approved for the management of IBS-C and CIC but was later withdrawn due to concerns about adverse cardiovascular events. After generating additional safety data and undergoing a review, tegaserod was re-approved for use in IBS-C with restricted labeling. This review summarizes the regulatory journey and provides an overview of the pharmacokinetic, physiologic, clinical, and safety data of tegaserod.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia

Ifat Geron et al.

Summary: This study reveals that activating mutations in Interleukin-7 receptor alpha can initiate preleukemia in primary human hematopoietic progenitors and cooperate with CDKN2A silencing in the progression into acute lymphoblastic leukemia (BCP-ALL).

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Oncology

Article The proteogenomic subtypes of acute leukemia

Ashok Kumar Jayavelu et al.

Summary: This study conducted a comprehensive proteogenomic analysis of bone marrow biopsies from 252 uniformly treated AML patients to uncover the molecular pathophysiology of AML and provide insights for future diagnosis and treatment. The analysis identified five proteomic AML subtypes, with one subtype (Mito-AML) associated with poor prognosis and heightened response to the BCL2 inhibitor venetoclax.

CANCER CELL (2022)

Add to Collection

Article Oncology

Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse

Valentina Gambacorta et al.

Summary: Immune escape is a major factor contributing to the relapse of AML after allo-HCT. In this study, PRC2 is identified as the key epigenetic driver of this immune escape modality. Inhibition of PRC2 can restore the expression of HLA class II molecules in AML relapse, providing a potential innovative approach for personalized epigenetic immunotherapies.

CANCER DISCOVERY (2022)

Add to Collection

Article Multidisciplinary Sciences

Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells

Clement Larrue et al.

Summary: The study reveals the critical role of ADM-CALCRL in post-chemotherapy persistence of drug-tolerant leukemic stem cells, suggesting it as a promising therapeutic target to prevent relapse in AML. Targeting adrenomedullin-calcitonin receptor-like receptor reduces the frequency of relapse-initiating cells and improves chemotherapy response in AML preclinical models.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence

Cihangir Duy et al.

Summary: The study revealed that primary AML cells can enter a senescence-like phenotype after chemotherapy, leading to a decrease in leukemia stem cells and an increase in subpopulations with senescence-like cells. Moreover, ATR inhibitors can transiently impair the persistence of AML cells.

CANCER DISCOVERY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy

Liguo Wang et al.

Summary: The study highlights the introduction of proteolysis-targeting chimeras (PROTACs) targeting of CDK2, which can promote differentiation of AML cells, providing a promising approach for treatment.

NATURE CHEMICAL BIOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Advances in acute myeloid leukemia

Laura F. Newell et al.

Summary: AML, a rare and potentially catastrophic diagnosis, has seen recent advancements in personalized therapy and novel treatment options due to discoveries of molecular drivers of the disease.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Oncology

Emerging agents and regimens for AML

Hongtao Liu

Summary: Recent advancements in AML treatment have led to expanded therapeutic options for patients through genomic and molecular research, including targeted therapies, immunotherapy, and combinations of therapeutic agents from different classes, resulting in improved survival rates.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article

Expression of Transient Receptor Potential Channel of Melastatin number 8 (TRPM8) in Non- Melanoma Skin Cancer: A Clinical and Immunohistochemical study

Aiat Shaban Hemida et al.

JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY (2021)

Add to Collection

Article Hematology

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Hardikkumar Jetani et al.

Summary: Siglec-6 can serve as a novel target for CAR T cell therapy in AML, effectively eliminating AML cells without affecting normal hematopoietic stem cells. This therapy may also be applicable to CLL, with limited on-target/off-tumor reactivity on normal mature hematopoietic cells.

BLOOD (2021)

Add to Collection

Review Hematology

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz et al.

Summary: Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) are behind those with acute lymphoblastic leukemia (ALL) due to disease heterogeneity, lack of targeted therapies, and slow development of immunotherapy. Further intensification of conventional chemotherapy is unlikely to reduce relapse rates, but comprehensive genomic analyses and understanding of leukemic stem cells may lead to more effective tailored therapies in the future. New therapies like venetoclax and CAR T-cell therapy offer hope for improved outcomes in pediatric AML treatment.

BLOOD (2021)

Add to Collection

Editorial Material Oncology

Stepwise evolution of therapy resistance in AML

Philippe Gui et al.

Summary: Relapse of AML patients to FLT3i treatment is a result of a long-term and stepwise process, where residual cancer cells initially survive and subsequently expand due to resistance. Joshi et al. demonstrate that early resistance to gilteritinib, driven by the microenvironment, evolves into mutation-driven late resistance through a multi-faceted approach.

CANCER CELL (2021)

Add to Collection

Article Oncology

Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression

L. C. Stetson et al.

Summary: The prognosis of most patients with AML is poor due to frequent disease relapse, which is thought to be caused by the persistence of leukemia initiating cells (LIC's). This study identified RNA clonal evolution in LICs during AML progression, with common signaling networks involving metabolism, apoptosis and chemokine signaling that evolved during AML progression being potential targets for improving therapeutic strategies. Additionally, co-targeting BCL2 and CXCR4 signaling may help overcome therapeutic challenges with AML heterogeneity.

LEUKEMIA (2021)

Add to Collection

Review Cell Biology

Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers

C. Glenn Begley et al.

Summary: Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines, but insufficient consideration by academic researchers of the required processes may hinder its success. Critical factors for successful repurposed medicines include financial, intellectual property, and clinical considerations.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Oncology

LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-kappa B signaling axis

Guojin Wu et al.

Summary: The study reveals that LILRB3 modulates AML cell survival and anti-leukemic T-cell responses through regulation of TRAF2-cFLIP-NF-kappa B signaling. Blocking LILRB3 signaling with antagonizing antibodies hampers AML progression.

NATURE CANCER (2021)

Add to Collection

Article Endocrinology & Metabolism

Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinoma

Hong Xie et al.

Summary: The accumulation of glycogen is a consistent feature of clear cell renal cell carcinoma (ccRCC). However, it has been found that glycogen is not essential for tumor cell proliferation and survival in ccRCC, both in vivo and in vitro. This suggests that glycogen build-up in ccRCC tumor cells may be a secondary and seemingly non-essential consequence of HIF-1 alpha signaling.

NATURE METABOLISM (2021)

Add to Collection

Review Oncology

New strategies to treat AML: novel insights into AML survival pathways and combination therapies

Ramya Nair et al.

Summary: The treatment of acute myeloid leukemia (AML) is challenging due to its heterogeneity, leading to a shift towards personalized treatment based on genomic signature. Novel insights into AML survival pathways, including drug resistance and immune system evasion, are being revealed. The combination of drugs or treatments has shown enhanced clinical efficiencies, prompting further investigation into targeted pathways for increased treatment response.

LEUKEMIA (2021)

Add to Collection

Article Oncology

Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia

Bader Alanazi et al.

LEUKEMIA (2020)

Add to Collection

Article Hematology

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Gail J. Roboz et al.

BLOOD (2020)

Add to Collection

Article Oncology

Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia

Basit Salik et al.

CANCER CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Molecular mechanisms underlying menthol binding and activation of TRPM8 ion channel

Lizhen Xu et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Mechanoactivation of NOX2-generated ROS elicits persistent TRPM8 Ca2+ signals that are inhibited by oncogenic KRas

Stephen J. P. Pratt et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel

Ying Yin et al.

SCIENCE (2019)

Add to Collection

Article Oncology

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia

Yue Huang et al.

CANCER CELL (2019)

Add to Collection

Article Oncology

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia

Irene Baccelli et al.

CANCER CELL (2019)

Add to Collection

Article Biochemistry & Molecular Biology

A fully human transgene switch to regulate therapeutic protein production by cooling sensation

Peng Bai et al.

NATURE MEDICINE (2019)

Add to Collection

Article Multidisciplinary Sciences

Inducing and exploiting vulnerabilities for the treatment of liver cancer

Cun Wang et al.

NATURE (2019)

Add to Collection

Article Oncology

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

Andrei V. Krivtsov et al.

CANCER CELL (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Drug repurposing: progress, challenges and recommendations

Sudeep Pushpakom et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection

Article Hematology

Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2

Meidan Ying et al.

BLOOD (2018)

Add to Collection

Article Cell Biology

Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche

Allison L. Boyd et al.

NATURE CELL BIOLOGY (2017)

Add to Collection

Article Biochemical Research Methods

TRP channel mediated neuronal activation and ablation in freely behaving zebrafish

Shijia Chen et al.

NATURE METHODS (2016)

Add to Collection

Review Oncology

TRPM8: a potential target for cancer treatment

Zhaoguo Liu et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

The TRPM2 ion channel is required for sensitivity to warmth

Chun-Hsiang Tan et al.

NATURE (2016)

Add to Collection

Article Multidisciplinary Sciences

VAMP7 regulates constitutive membrane incorporation of the cold-activated channel TRPM8

Debapriya Ghosh et al.

NATURE COMMUNICATIONS (2016)

Add to Collection

Article Cell Biology

TRP channel-associated factors are a novel protein family that regulates TRPM8 trafficking and activity

Dimitra Gkika et al.

JOURNAL OF CELL BIOLOGY (2015)

Add to Collection

Review Oncology

Roles of TRPM8 Ion Channels in Cancer: Proliferation, Survival, and Invasion

Nelson S. Yee

CANCERS (2015)

Add to Collection

Article Cell Biology

Direct inhibition of the cold-activated TRPM8 ion channel by Gαq

Xuming Zhang et al.

NATURE CELL BIOLOGY (2012)

Add to Collection

Review Gastroenterology & Hepatology

Tegaserod - A new 5-HT4 agonist

BE Lacy et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.